At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CMPS COMPASS Pathways plc
Pre-Mkt 01-16 05:08:18 EST
7.31
-0.32
-4.19%
High7.75Low7.16Vol1.46M
Open7.70D1 Closing7.63Amplitude7.73%
Mkt Cap701.88MTradable Cap427.01MTotal Shares96.02M
T/O10.84MT/O Rate2.49%Tradable Shares58.41M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Cantor Fitzgerald Sticks to Its Buy Rating for COMPASS Pathways (CMPS)
TIPRANKS  ·  01-08
Cantor Fitzgerald Sticks to Its Buy Rating for COMPASS Pathways (CMPS)
RBC Capital Sticks to Their Buy Rating for COMPASS Pathways (CMPS)
TIPRANKS  ·  01-08
RBC Capital Sticks to Their Buy Rating for COMPASS Pathways (CMPS)
Stifel Nicolaus Remains a Buy on COMPASS Pathways (CMPS)
TIPRANKS  ·  01-08
Stifel Nicolaus Remains a Buy on COMPASS Pathways (CMPS)
Compass Pathways Says FDA Accepts Application for PTSD Treatment; Shares Up Pre-Bell
MT Newswires Live  ·  01-07
Compass Pathways Says FDA Accepts Application for PTSD Treatment; Shares Up Pre-Bell
Compass Pathways Plc - on Jan 5, Co Entered Third Amendment to Loan and Security Agreement With Hercules
THOMSON REUTERS  ·  01-07
Compass Pathways Plc - on Jan 5, Co Entered Third Amendment to Loan and Security Agreement With Hercules
Compass Pathways Plc - Secures $150 Mln Loan Agreement - SEC Filing
THOMSON REUTERS  ·  01-07
Compass Pathways Plc - Secures $150 Mln Loan Agreement - SEC Filing
Compass Pathways unveils investor presentation highlighting COMP360 Phase 3 results in treatment-resistant depression
Reuters  ·  01-07
Compass Pathways unveils investor presentation highlighting COMP360 Phase 3 results in treatment-resistant depression
Compass Pathways Expands Loan Facility With Hercules Capital to $150 Million
Reuters  ·  01-07
Compass Pathways Expands Loan Facility With Hercules Capital to $150 Million
Compass Pathways Announces FDA Acceptance of Ind Application for Ptsd and Hosts Webinar on Ptsd and Trd
THOMSON REUTERS  ·  01-07
Compass Pathways Announces FDA Acceptance of Ind Application for Ptsd and Hosts Webinar on Ptsd and Trd
Compass Pathways Plc - to Be Launch-Ready for Comp360 for Trd by Year-End
THOMSON REUTERS  ·  01-07
Compass Pathways Plc - to Be Launch-Ready for Comp360 for Trd by Year-End
Compass Pathways Partners with Radial Health to Advance Psilocybin Treatment Delivery
Reuters  ·  01-06
Compass Pathways Partners with Radial Health to Advance Psilocybin Treatment Delivery
Compass Pathways Establishes Strategic Collaboration With Radial to Innovate Patient Experience and Inform Potential Delivery Model of Comp360
THOMSON REUTERS  ·  01-06
Compass Pathways Establishes Strategic Collaboration With Radial to Innovate Patient Experience and Inform Potential Delivery Model of Comp360
A small company can now advance its psychedelic into Phase 3. Here's why that matters to other psychedelic biotechs.
Dow Jones  ·  01-05
A small company can now advance its psychedelic into Phase 3. Here's why that matters to other psychedelic biotechs.
Compass Pathways Hosts Webinar on Commercial Preparations for TRD and PTSD Clinical Trials
Reuters  ·  2025-12-09
Compass Pathways Hosts Webinar on Commercial Preparations for TRD and PTSD Clinical Trials
Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (Trd) and Clinical Trial Plans for Post-Traumatic Stress Disorder (Ptsd) on January 7, 2026, 10:00Am Et
THOMSON REUTERS  ·  2025-12-09
Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (Trd) and Clinical Trial Plans for Post-Traumatic Stress Disorder (Ptsd) on January 7, 2026, 10:00Am Et
Compass Pathways to Join Evercore and Piper Sandler Healthcare Conferences
Reuters  ·  2025-11-20
Compass Pathways to Join Evercore and Piper Sandler Healthcare Conferences
Compass Pathways Is Maintained at Overweight by Morgan Stanley
Dow Jones  ·  2025-11-06
Compass Pathways Is Maintained at Overweight by Morgan Stanley
RBC Adjusts Price Target on COMPASS Pathways to $16 From $15, Maintains Outperform Rating
MT Newswires Live  ·  2025-11-05
RBC Adjusts Price Target on COMPASS Pathways to $16 From $15, Maintains Outperform Rating
Compass Pathways to Participate in Stifel 2025 Healthcare Conference
Reuters  ·  2025-11-05
Compass Pathways to Participate in Stifel 2025 Healthcare Conference
Stock Track | Compass Pathways Plunges 5.28% After Reporting Larger-Than-Expected Q3 Loss
Stock Track  ·  2025-11-05
Stock Track | Compass Pathways Plunges 5.28% After Reporting Larger-Than-Expected Q3 Loss

Introduction

Company Name.
COMPASS Pathways plc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Issue price:
--